Starling Oncology has secured a $25 million revolving Credit facility, enhancing its financial flexibility. This support allows the company to address Working Capital needs and general corporate expenses.
Key Highlights
- The revolving credit Facility allows Starling Oncology access to up to $25 million, which can be drawn upon as needed.
- Loans under this facility incur interest at Term SOFR plus 3.95%, reflecting the company's commitment to cost-efficient financing.
- Starling Oncology, Inc. has entered into a new credit agreement enabling it to access a revolving line of credit facility totaling up to $25 million.
Starling Oncology, Inc. has entered into a new credit agreement enabling it to access a revolving line of credit facility totaling up to $25 million. This agreement aims to provide the company with additional financial flexibility, essential for managing its operational needs and enhancing growth strategies. Starling Oncology may draw on this facility as necessary, although it is not obligated to utilize the full amount offered.
Such flexibility is key for managing working capital and general corporate purposes in a volatile market.
$25 Million Credit Facility Details
The revolving Loan agreement secures an access limit of up to $25 million, ensuring Starling Oncology can meet any short-term Liquidity needs. This revolving line will ultimately mature on August 20, 2029, offering a relatively lengthy timeframe for repayment and use. The structure supports an ongoing borrowing base formula, directly linked to the company's accounts receivables.
Such arrangements are vital for sustaining operations without immediately impacting cash flow.
Interest Rates and Fees
Starling Oncology will incur an Interest Rate equal to Term SOFR plus 3.95% on any utilized portion of the credit facility. To safeguard lender interests, the facility comes with further stipulations: in the event of a default, the applicable interest rate increases by 5%. The agreement mandates customary fees, including a Collateral monitoring fee fixed at 0.0833% of the average borrowing base monthly.
An unused line fee and a minimum use fee apply if borrowing dips below $5 million. Such financial arrangements ensure that Starling Oncology manages its costs effectively while retaining flexibility.
Operational Implications
This capital injection through the revolving credit agreement signals Starling Oncology's proactive stance on financial management as it strives to optimize working capital. The requirement for specific lockbox arrangements pertaining to receivables enhances Cash Flow security and oversight significantly. Establishing these controls may also facilitate better operational management while limiting potential financial liabilities.
Given that the borrowing terms are primarily anchored in the company’s receivables, successful management of these accounts will be essential for maximizing the benefits of the credit facility.
Future Actions to Monitor
These updates will be critical as they reflect the real-time performance of the credit facility and its operational integration. Management's adherence to the agreed-upon financial ratios will be critical in maintaining the facility's terms and ensuring ongoing financial flexibility without jeopardizing operational viability.






Please wait processing your request...